Xeris Biopharma Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $335.4M+65.2% YoYTTM through 30 Jun 2026
Net Income -$17.2MTTM through 30 Jun 2026
Free Cash Flow $27.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 85.4% |
| EBITDA Margin | 11.3% |
| Operating Margin | 8.5% |
| Net Margin | -5.1% |
Returns
4.1%ROE
0.1%ROA
-14.2%ROIC
Balance Sheet Health
Debt / Equity18.85x
Current Ratio2.39x
Net Debt$147.1M
Cash & Equivalents$121.7M
Quality Metrics
Altman Z-Score1.24
Piotroski F-Score5 / 9
FCF Margin8.3%
Rule of 4023.8
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $291.8M
Diluted EPS-$0.10TTMFY2025: $0.00
Dividend
No dividend
Capital Allocation
R&D Spend$34.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Recorlev | $139.3M | View detailsPrimary growth engine with commercial team expansion executed to accelerate adoption. | |
| Gvoke | $94.1M | +14.0% | View detailsContinued stable demand and favorable net pricing. |
| Keveyis | $47.6M | -4.0% | View detailsMaintains a solid patient base despite generic competition. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.